Successful Chemotherapy for Small-Cell Lung Cancer in an Elderly Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

Tanizawa, Kiminobu; Fukunaga, Kentaro; Okumura, Noriko; Sugimura, Mitsuko; Tanaka, Eisaku; Hajiro, Takashi; Sakuramoto, Minoru; Minakuchi, Masayoshi; Hashimoto, Seishu; Yasuda, Takehiro; Kaji, Yuji; Ikezoe, Kohei; Sato, Eizaburo; Nakajima, Toshifumi; Terada, Yoshio

doi:10.2169/internalmedicine.49.3497

Cited by 3 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not investigate the pharmacokinetics of etoposide. However, in previous reports, the etoposide level could not be controlled by hemodialysis, as it did not show membrane permeability . The dosage for etoposide in patients with normal renal function is 100 mg/m 2 on day 1 for 3 consecutive days .…”

Section: Discussionmentioning

confidence: 89%

“…To assist in carboplatin dosing, a Pubmed literature search was performed using the search terms carboplatin, etoposide, hemodialysis, and pharmacokinetic, which resulted in eight matches. Four studies were eliminated from the literature review; one was due to the use of both hemodialysis and peritoneal dialysis, two other studies looked at peritoneal dialysis only, and one article was in Japanese with no English translation . The remaining articles were four case reports that administered carboplatin doses ranging from 100m–300 mg/m 2 on day 1 and etoposide 50 mg/m 2 on day 1 and day 3 .…”

Section: Discussionmentioning

confidence: 99%

“…Four studies were eliminated from the literature review; one was due to the use of both hemodialysis and peritoneal dialysis, two other studies looked at peritoneal dialysis only, and one article was in Japanese with no English translation. [12][13][14][15] The remaining articles were four case reports that administered carboplatin doses ranging from 100m-300 mg/m 2 on day 1 and etoposide 50 mg/m 2 on day 1 and day 3. [16][17][18][19] Our patient's dosing was based on several published case reports ( Table 2).…”

Section: Discussionmentioning

confidence: 99%

“…However, in previous reports, the etoposide level could not be controlled by hemodialysis, as it did not show membrane permeability. [11][12][13] The dosage for etoposide in patients with normal renal function is 100 mg/m 2 on day 1 for 3 consecutive days. 20 However, as etoposide has been reported to be poorly dialyzed, and previous studies involving renal dosing of etoposide employed 50 mg/m 2 on days 1 and 3, 18, 19 the dose of etoposide in our patient remained consistent with this recommendation.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

et al. 2013

View full text Add to dashboard Cite

With refinements and advances in hemodialysis techniques, survival for patients with end-stage renal disease has improved significantly. To our knowledge, however, no prospective trials have been performed in patients receiving hemodialysis who are also diagnosed with cancer and are candidates for chemotherapy. We describe a 73-year-old man who was diagnosed with high-grade neuroendocrine carcinoma, metastatic to the bone and lymph nodes, and was undergoing hemodialysis. Although cisplatin is more commonly used in the treatment of metastatic neuroendocrine cancers, it may not be the best option in patients who suffer from renal insufficiency. Carboplatin is a second-generation, nonnephrotoxic platinum analog that can be hemodialyzed, although no formal guidelines are available regarding the dosing for patients receiving hemodialysis. This case describes a patient who was treated with five cycles of combination carboplatin 115 mg/m2 on day 1 and etoposide 50 mg/m2 on day 1 and day 3 of a 28-day cycle. Dialysis was performed for 3.5 hours starting 90 minutes after completion of carboplatin on day 1. Pharmacokinetic assessments were performed at 1, 2, 4, and 12 hours after chemotherapy infusion on day 1 of cycle 1. Total carboplatin concentrations in plasma and platinum ultrafiltrate were measured. The plasma concentration of free platinum at the end of the infusion was 31,000 ng/ml, and the area under the plasma concentration–time curve was 2.9 minute·mg/ml. No significant carboplatin-related toxicities were reported. This case report indicates that carboplatin can be safely administered in patients receiving hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

et al. 2013

View full text Add to dashboard Cite

show abstract

Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis

Choi

Park

et al. 2014

Ewha Med J

View full text Add to dashboard Cite

Carboplatin plus etoposide induced a complete response in a hemodialysis patient with limited stage small cell lung cancer–a case report and literature review–

Sunada

Iwazu

Nakamura

et al. 2017

Nihon Toseki Igakkai Zasshi

View full text Add to dashboard Cite

Keywords： end-stage renal failure, hemodialysis, small cell lung cancer, carboplatin, etoposide 〈Abstract〉 We present a case in which a hemodialysis patient with small cell lung cancer(SCLC)was successfully treated with chemotherapy. A mass was detected in the right lower lung field in a 68-year-old hemodialysis-dependent female with end-stage renal failure caused by diabetic nephropathy during a routine chest X-ray. Limited stage SCLC was diagnosed after bronchoscopy and computed tomography. The patient received concurrent chemoradiotherapy involving carboplatin plus etoposide. A complete response was achieved after one course of chemoradiotherapy. Although the patient received four courses of chemotherapy without suffering any severe adverse effects, she stopped receiving radiotherapy because she could not attend the hospital frequently. Sixteen months after the start of the chemoradiotherapy, the lung mass disappeared.

show abstract

Successful Chemotherapy for Small-Cell Lung Cancer in an Elderly Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

Abstract: Abstract

Cited by 3 publications

References 26 publications

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis

Carboplatin plus etoposide induced a complete response in a hemodialysis patient with limited stage small cell lung cancer–a case report and literature review–

Contact Info

Product

Resources

About